Sanofi stock

SAN · Euronext Paris · EUR

Compare Sanofi
€86.56Change from previous close: −1.99%Absolute change: −€1.76

Close · November 17, 2026

Price history

−2.17% over the period

1 year: from €89.89 (November 17, 2025) to €87.94 (November 17, 2026), −2.17%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026€87.94
October 30, 2026€79.74
September 30, 2026€72.64
August 31, 2026€76.81
July 31, 2026€74.47
June 30, 2026€75.08
May 29, 2026€75.29
April 30, 2026€79.82
March 31, 2026€82.72
February 27, 2026€82.20
January 30, 2026€79.20
December 31, 2025€82.72
November 28, 2025€85.76
November 17, 2025€89.89

At a glance

  • The company

    Develops, manufactures and markets therapeutic solutions and vaccines for immunology, rare diseases, neurology and oncology

  • Latest results

    Quarter to September 30, 2026 · EPS €3.55 (estimate €2.79)

TickerLandia's take on Sanofi

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€69.75
52-wk high€90.07

−3.90% from the 52-week high

Analysts · 24 analysts

Average target€96.36+11.32% vs. price

Buy 12 · Hold 12 · Sell 0 · Buy

TickerLandia Fingerprint: Sanofi

Compared with similar companies: low price, high dividend, and low profitability.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Sanofi is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Sanofi's P/E today is 13.8, below the median of its last 10 fiscal years (19.3; between 8.01 and 40.0 from 2016 to 2025). Sanofi's P/E (trailing 12 months): 25.5, +19% against the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

Sanofi's metrics compared with similar companies
MetricSanofiPosition in the groupBand
P/E (trailing 12 months)25.5Middle
Forward P/E9.34Low
Operating margin22.3%Middle
ROE5.7%Low
Debt/equity0.27Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sanofi. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€15.23B

Latest quarter · Q3 2026

Net income

€3.02B

Latest quarter · Q3 2026

Quarterly net margin

19.8%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€106.04B
P/E
25.5
EPS
€3.46
Volume
1.52M
Daily trading
€228.21M
Dividend yield
4.76%
Last ex-dividend on May 5, 2026

How Sanofi is changing

All results
  • Revenue grew 4.6% a year on average over the last 5 years

  • Operating margin fell from 25.2% to 13.6%

  • Profits turn into cash: free cash flow equal to 133% of net income

Returns

Sanofi returns with dividends

€1,000 invested in Sanofi 5 years ago, on November 17, 2021, would be worth €1,200 today with dividends reinvested: +20.01% in total, +3.72% per year. On price alone it would be €976 (−2.41%).

PeriodSanofiCAC 40€1,000 becomes
1 month+23.84%+5.35%€1,238
6 months+17.04%+4.23%€1,170
Year to date+6.31%+1.71%€1,063
1 year+3.27%+2.09%€1,033
3 years+17.29%+14.59%€1,173
5 years+20.01%+15.82%€1,200
10 years+70.70%+83.07%€1,707

Over the last 6 months it has done better than 45% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment

The chart in detail

Sanofi: technical analysis

Sanofi shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 21.0% below its all-time closing high (€109.62, March 7, 2025).

Trend
No clear trend
RSI (14 sessions)
71
Above 70: a strong rise in a short time
vs 200-session average
+12.47%

Active signals

  • RSI above 70: the stock has risen a lot in a short time.

    since October 30, 2026

Support and resistance

Price areas where Sanofi has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€86.56
  3. Support€83.90−3.07%2 touches, last on April 23, 2026
  4. Support€82.57−4.60%2 touches, last on February 27, 2026
  5. Support€79.77−7.84%2 touches, last on August 26, 2026

Volatility and risk

Over the last year it has moved less than the CAC 40.

Beta (1 year) vs CAC 40
0.40
Volatility (60 sessions, annualised)
23.1%
Largest fall in the last year
−22.14%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Sanofi: seasonality

Average monthly price change over 37 years

−0.1%Jan−0.6%Feb+1.8%Mar+1.7%Apr−0.9%May−0.9%Jun+2.2%Jul−1.0%Aug+1.1%Sep+1.9%Oct+0.9%Nov+2.1%Dec

Over the last 37 years, the strongest month for Sanofi has been July: +2.16% on average, positive in 21 years out of 37. The weakest has been August: −0.98% on average, positive in 21 years out of 37. November, the current month, has been positive in 19 years out of 36 (+0.87% on average).

Show chart data
MonthAverageMedianPositive years
January−0.09%−0.75%16 of 36
February−0.58%−0.85%17 of 37
March+1.77%+1.31%22 of 37
April+1.69%+0.82%21 of 37
May−0.85%−1.24%14 of 37
June−0.91%−1.02%17 of 37
July+2.16%+0.82%21 of 37
August−0.98%+0.95%21 of 37
September+1.12%+0.54%20 of 37
October+1.94%+2.67%25 of 37
November+0.87%+0.64%19 of 36
December+2.12%+3.84%24 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Sanofi and its competitors

Employing 74,846 people, Sanofi researches, develops, manufactures and markets therapeutic solutions, with a focus on immunology and inflammation, rare diseases, neurology, oncology and vaccines. Its vaccine range includes pediatric vaccines against polio, pertussis and Hib, a hexavalent combination vaccine, protection against respiratory syncytial virus and the Fluzone flu vaccine. Dupixent, developed with Regeneron for diseases driven by type 2 inflammation, is one of its products.

Headquarters
Paris, France
Employees
74,846
Founded
1994
Chief executive
Belen Garijo Lopez
Sanofi and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
SanofiSAN$116.52B22.3%25.5+17.04%
GSKGSK$102.04B30.5%18.0+0.35%
Novo NordiskNOVO.B$184.87B50.8%11.2−7.92%
BayerBAYN$61.54B16.5%—+48.87%
AstraZenecaAZN$287.12B25.8%26.6+1.25%
NovartisNOVN$305.16B34.0%32.6+14.23%

Same industry or related industries, similar size. Compare Sanofi with its competitors · Full profile